Literature DB >> 2230867

Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix.

J Bourhis1, M G Le, M Barrois, A Gerbaulet, D Jeannel, P Duvillard, V Le Doussal, D Chassagne, G Riou.   

Abstract

The prognostic effect of c-myc oncogene overexpression was assessed in a multivariate analysis of 93 patients with invasive carcinoma of the cervix, stage Ib, IIa, and IIb proximal. The treatment was based on the association of brachytherapy-colpohysterectomy and lymphadenectomy. Analysis of c-myc gene expression was done using Northern and slot blot hybridization techniques. Overexpression of c-myc (ie, levels at least three times the mean observed in normal tissues) was present in 33% of the tumors. The proportion of carcinomas with c-myc overexpression significantly increased with the size of the primary tumor (P = .04). No relationship was found between c-myc overexpression and the other clinical and histologic parameters, including the nodal status. The relative risk of relapse (overall, pelvic failure, distant metastases) was analyzed in a Cox's proportional hazards model. Three factors were significantly related to the risk of overall relapse when the multivariate analysis was performed, namely, the tumor size, the nodal status, and c-myc expression. A combination of c-myc expression and the nodal status provided a very accurate indication of the risk of relapse. Indeed, patients with negative nodes had a 3-year disease-free survival rate of 93% (95% confidence interval [Cl], 79% to 98%) when c-myc was expressed at a normal level, whereas this rate was only 51% (95% Cl, 26% to 63%) when c-myc was overexpressed (log-rank test, P = .02). In addition, in the subgroup of patients with positive nodes, this rate was 44% (95% Cl, 25% to 77%) and 15% (95% Cl, 4% to 49%) when c-myc gene was expressed at normal level, or overexpressed, respectively. Finally, c-myc gene overexpression was, in the multivariate analysis, the first factor selected by the model regarding the risk of distant metastases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230867     DOI: 10.1200/JCO.1990.8.11.1789

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  MYC and metastasis.

Authors:  Anita Wolfer; Sridhar Ramaswamy
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

2.  K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc.

Authors:  Kirti Magudia; Aurelia Lahoz; Alan Hall
Journal:  J Cell Biol       Date:  2012-07-23       Impact factor: 10.539

Review 3.  Tumor microenvironment: becoming sick of Myc.

Authors:  Jonathan R Whitfield; Laura Soucek
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

4.  c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia.

Authors:  Kirsten Kübler; Sally Heinenberg; Christian Rudlowski; Mignon-Denise Keyver-Paik; Alina Abramian; Sabine Merkelbach-Bruse; Reinhard Büttner; Walther Kuhn; Hans-Ulrich Schildhaus
Journal:  Oncotarget       Date:  2015-01-20

5.  RNA Exosome Component EXOSC4 Amplified in Multiple Cancer Types Is Required for the Cancer Cell Survival.

Authors:  Kenzui Taniue; Tanzina Tanu; Yuki Shimoura; Shuhei Mitsutomi; Han Han; Rika Kakisaka; Yusuke Ono; Nobue Tamamura; Kenji Takahashi; Youichiro Wada; Yusuke Mizukami; Nobuyoshi Akimitsu
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

Review 6.  Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials.

Authors:  Jianming Tang; Mingzhu Li; Chao Zhao; Danhua Shen; Lei Liu; Xiujun Zhang; Lihui Wei
Journal:  Viruses       Date:  2022-01-25       Impact factor: 5.048

7.  Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter.

Authors:  W Nürnberg; M Artuc; G Vorbrueggen; F Kalkbrenner; K Moelling; B M Czarnetzki; D Schadendorf
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

8.  The therapeutic potential of exosomal miR-22 for cervical cancer radiotherapy.

Authors:  Hiromi Konishi; Masami Hayashi; Kohei Taniguchi; Mayumi Nakamura; Yuki Kuranaga; Yuko Ito; Yoichi Kondo; Hiroshi Sasaki; Yoshito Terai; Yukihiro Akao; Masahide Ohmichi
Journal:  Cancer Biol Ther       Date:  2020-11-16       Impact factor: 4.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.